Targeting miR-144-5p/ACSM1 Axis Alleviates Doxorubicin-Induced Heart Failure by Inhibiting Lipid Peroxidation

Abstract

Objective

This study investigates the role of miR-144-5p in doxorubicin (DOX)-induced heart failure and explores its potential mechanisms by targeting ACSM1 and inhibiting lipid peroxidation.

Methods

Bioinformatics analysis was performed using the gene expression omnibus dataset GSE136547 to identify differentially expressed miRNAs in heart failure. DOX-induced in vitro and in vivo heart failure models were used to study the effects of miR-144-5p on cardiomyocyte viability, apoptosis, and lipid peroxidation. The targeting relationship between miR-144-5p and ACSM1 was verified using dual-luciferase reporter assays. Cardiac function was assessed by echocardiography, and biochemical markers of heart failure were measured using ELISA. The GO and KEGG enrichment analyses of ACSM1 were performed via the bioinformatic tools GeneMANIA and STRING.

Results

miR-144-5p was significantly upregulated in DOX-treated cardiomyocytes and mouse hearts. Inhibition of miR-144-5p attenuated DOX-induced cardiomyocyte apoptosis, lipid peroxidation, and cardiac dysfunction. ACSM1 was identified as a direct target of miR-144-5p, and its expression was downregulated by DOX. Silencing ACSM1 abolished the protective effects of the miR-144-5p inhibitor on the viability, apoptosis, and lipid peroxidation of cardiomyocytes. Furthermore, miR-144-5p inhibition improved cardiac function in DOX-treated mice, as evidenced by reduced left ventricular dysfunction and decreased levels of heart failure markers (BNP, LDH, Ang II, and ALD).

Conclusions

Our findings demonstrate that inhibiting miR-144-5p alleviates DOX-induced heart failure by targeting ACSM1 and suppressing lipid peroxidation. The miR-144-5p/ACSM1 axis may represent a novel therapeutic target for heart failure. Future studies should focus on further elucidating the mechanisms underlying this axis and exploring its potential clinical applications.

Keywords

Heart failure / Lipid peroxidation / Doxorubicin / MiR-144-5p / ACSM1

References

[1] Snipelisky D, Chaudhry SP, Stewart GC. The Many Faces of Heart Failure. Card Electrophysiol Clin., 2019, 11(1): 11-20

[2] Yan F, Zhu H, He Y, et al.. Combination of tolvaptan and valsartan improves cardiac and renal functions in doxorubicin-induced heart failure in mice. Eur J Histochem., 2022, 66(4): 3563

[3] Conrad N, Judge A, Tran J, et al.. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet., 2018, 391(10120572-580

[4] Taylor CJ, Ordóñez-Mena JM, Roalfe AK, et al.. Trends in survival after a diagnosis of heart failure in the United Kingdom 2000–2017: population based cohort study. BMJ., 2019, 367: l223

[5] Yang YY, Guo QY, Lu M, et al.. Expression of miR-320 and miR-204 in myocardial infarction and correlation with prognosis and degree of heart failure. Front Genet., 2023, 13: 1094332

[6] Vishnoi A, Rani S. MiRNA Biogenesis and Regulation of Diseases: An Overview. Methods Mol Biol., 2017, 1509: 1-10

[7] Colpaert RMW, Calore M. Epigenetics and microRNAs in cardiovascular diseases. Genomics., 2021, 113(2): 540-551

[8] Wojciechowska A, Braniewska A, Kozar-Kaminska K. MicroRNA in cardiovascular biology and disease. Adv Clin Exp Med., 2017, 26(5): 865-874

[9] Li HP, Fan JH, Zhao YR, et al.. Nuclear miR-320 Mediates Diabetes-Induced Cardiac Dysfunction by Activating Transcription of Fatty Acid Metabolic Genes to Cause Lipotoxicity in the Heart. Circ Res., 2019, 125(12): 1106-1120

[10] Zhang XK, Ji RP, Liao XH, et al.. MicroRNA-195 Regulates Metabolism in Failing Myocardium Via Alterations in Sirtuin 3 Expression and Mitochondrial Protein Acetylation. Circulation., 2018, 137(19): 2052-2067

[11] Zhang B, Mao SY, Liu XD, et al.. MiR-125b inhibits cardiomyocyte apoptosis by targeting BAK1 in heart failure. Mol Med., 2021, 27(1): 72

[12] Qiao L, Hu SQ, Liu SY, et al.. microRNA-21-5p dysregulation in exosomes derived from heart failure patients impairs regenerative potential. J Clin Invest., 2019, 129(62237-2250

[13] Liu L, Sun S, Li X. LncRNA ZFAS1 ameliorates injury led by non-alcoholic fatty liver disease via suppressing lipid peroxidation and inflammation. Clin Res Hepatol Gastroenterol., 2023, 47(1102067

[14] Ahmed AI, Dowidar MF, Negm AF, et al.. Bone marrow mesenchymal stem cells expressing Neat-1, Hotair-1, miR-21, miR-644, and miR-144 subsided cyclophosphamide-induced ovarian insufficiency by remodeling the IGF-1-kisspeptin system, ovarian apoptosis, and angiogenesis. J Ovarian Res., 2024, 17(1): 184

[15] Wu X, Zhang Y, Wang P, et al.. Clinical and preclinical evaluation of miR-144-5p as a key target for major depressive disorder. CNS Neurosci Ther., 2023, 29(113598-3611

[16] Cortes-Funes H, Coronado C. Role of anthracyclines in the era of targeted therapy. Cardiovasc Toxicol., 2007, 7(2): 56-60

[17] Wen SY, Tsai CY, Pai PY, et al.. Diallyl trisulfide suppresses doxorubicin-induced cardiomyocyte apoptosis by inhibiting MAPK/NF-kappaB signaling through attenuation of ROS generation. Environ Toxicol., 2018, 33(1): 93-103

[18] Zhang S, Liu X, Bawa-Khalfe T, et al.. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med., 2012, 18(11): 1639-1642

[19] Damiani RM, Moura DJ, Viau CM, et al.. Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone. Arch Toxicol., 2016, 90(9): 2063-2076

[20] Zhao L, Tao X, Qi Y, et al.. Protective effect of dioscin against doxorubicin-induced cardiotoxicity via adjusting microRNA-140-5p-mediated myocardial oxidative stress. Redox Biol., 2018, 16: 189-198

[21] Lam PY, Kutchukian P, Anand R, et al.. Cyp1 Inhibition Prevents Doxorubicin-Induced Cardiomyopathy in a Zebrafish Heart-Failure Model. Chembiochem., 2020, 21(13): 1905-1910

[22] Xu S, Wang Y, Yu M, et al.. LongShengZhi capsule inhibits doxorubicin-induced heart failure by anti-oxidative stress. Biomed Pharmacother., 2020, 123109803

[23] Zhou JC, Jin CC, Wei XL, et al.. Mesaconine alleviates doxorubicin-triggered cardiotoxicity and heart failure by activating PINK1-dependent cardiac mitophagy. Front Pharmacol., 2023, 14: 1118017

[24] Abu-Halima M, Meese E, Saleh MA, et al.. Micro-RNA 150–5p predicts overt heart failure in patients with univentricular hearts. PLoS One., 2019, 14(10e0223606

[25] Agarwal V, Bell GW, Nam JW, et al.. Predicting effective microRNA target sites in mammalian mRNAs. Elife., 2015, 4e05005

[26] Zhang XJ, Li L, Wang AL, et al.. GSK2795039 prevents RIP1-RIP3-MLKL-mediated cardiomyocyte necroptosis in doxorubicin-induced heart failure through inhibition of NADPH oxidase-derived oxidative stress. Toxicol Appl Pharmacol., 2023, 463116412

[27] Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol., 2016, 13(6): 368-378

[28] Huang JP, Chang CC, Kuo CY, et al.. Exosomal microRNAs miR-30d-5p and miR-126a-5p Are Associated with Heart Failure with Preserved Ejection Fraction in STZ-Induced Type 1 Diabetic Rats. Int J Mol Sci., 2022, 23(147514

[29] Gao L, Li T, Li S, et al.. Schisandrin A protects against isoproterenol-induced chronic heart failure via miR-155. Mol Med Rep., 2022, 25(124

[30] Fan P, Zhang L, Cheng T, et al.. MiR-590-5p inhibits pathological hypertrophy mediated heart failure by targeting RTN4. J Mol Histol., 2021, 52(5955-964

[31] Zhang Q, Yin J, Zou Y. MiR-568 mitigated cardiomyocytes apoptosis, oxidative stress response and cardiac dysfunction via targeting SMURF2 in heart failure rats. Heart Vessels., 2023, 38(6): 857-868

[32] Gao Z, Jiang J, Hou L, et al.. Dysregulation of MiR-144-5p/RNF187 Axis Contributes To the Progression of Colorectal Cancer. J Transl Int Med., 2022, 10(1): 65-75

[33] Song L, Peng L, Hua S, et al.. miR-144-5p Enhances the Radiosensitivity of Non-Small-Cell Lung Cancer Cells via Targeting ATF2. Biomed Res Int., 2018, 2018: 5109497

[34] Chen J, Li X, Yang L, et al.. Long Non-coding RNA LINC01969 Promotes Ovarian Cancer by Regulating the miR-144-5p/LARP1 Axis as a Competing Endogenous RNA. Front Cell Dev Biol., 2020, 8625730

[35] Chen X, Zhang X, Qian Y, et al.. Ultrasound-targeted microbubble destruction-mediated miR-144-5p overexpression enhances the anti-tumor effect of paclitaxel on thyroid carcinoma by targeting STON2. Cell Cycle., 2022, 21(10): 1058-1076

[36] Liu GM, Lu TC, Sun ML, et al.. Ginsenoside Rd Inhibits Glioblastoma Cell Proliferation by Up-Regulating the Expression of miR-144-5p. Biol Pharm Bull., 2020, 43(101534-1541

[37] Zang D, Li J, Zhou C. Clinical expression of microRNA-144-5p and its regulatory effect on renal function in uremia. Ther Apher Dial., 2023, 27(2): 246-252

[38] Zhang L, Liu X, Wei Q, et al.. Arginine attenuates chronic mountain sickness in rats via microRNA-144-5p. Mamm Genome., 2023, 34(1): 76-89

[39] Li Q, Hu Z, Yang F, et al.. Circ_0066881 targets miR-144-5p/RORA axis to alleviate LPS-induced apoptotic and inflammatory damages in human periodontal ligament cells. Innate Immun., 2022, 28(5): 164-173

[40] Zhang D, Wu Y, Li Z, et al.. MiR-144-5p, an exosomal miRNA from bone marrow-derived macrophage in type 2 diabetes, impairs bone fracture healing via targeting Smad1. J Nanobiotechnology., 2021, 19(1): 226

[41] Xu Y, Jiang W, Zhong L, et al.. circ-AKT3 aggravates renal ischaemia-reperfusion injury via regulating miR-144-5p /Wnt/beta-catenin pathway and oxidative stress. J Cell Mol Med., 2022, 26(61766-1775

[42] Chang S, Chang M, Liu G, et al.. LncRNA OIP5-AS1 reduces renal epithelial cell apoptosis in cisplatin-induced AKI by regulating the miR-144-5p/PKM2 axis. Biomed J., 2022, 45(4): 642-653

[43] Chen JY, Ruan HJ, Chen SY, et al.. MiR-144-5p/CCL12 Signaling Axis Modulates Ischemic Preconditioning-Mediated Cardio-protection by Reducing Cell Viability, Enhancing Cell Apoptosis, Fibrosis, and Pyroptosis. Appl Biochem Biotechnol., 2023, 195(3): 1999-2014

[44] Edlich F. BCL-2 proteins and apoptosis: Recent insights and unknowns. Biochem Biophys Res Commun., 2018, 500(1): 26-34

[45] Eskandari E, Eaves CJ. Paradoxical roles of caspase-3 in regulating cell survival, proliferation, and tumorigenesis. J Cell Biol., 2022, 221(6e202201159

[46] Fan J, Li H, Nie X, et al.. MiR-665 aggravates heart failure via suppressing CD34-mediated coronary microvessel angiogenesis. Aging (Albany NY)., 2018, 10(9): 2459-2479

[47] He R, Ding C, Yin P, et al.. MiR-1a-3p mitigates isoproterenol-induced heart failure by enhancing the expression of mitochondrial ND1 and COX1. Exp Cell Res., 2019, 378(1): 87-97

[48] Li Y, Yan C, Fan J, et al.. MiR-221-3p targets Hif-1alpha to inhibit angiogenesis in heart failure. Lab Invest., 2021, 101(1): 104-115

[49] Fujino T, Takei YA, Sone H, et al.. Molecular identification and characterization of two medium-chain acyl-CoA synthetases, MACS1 and the Sa gene product. J Biol Chem., 2001, 276(38): 35961-35966

[50] Boomgaarden I, Vock C, Klapper M, et al.. Comparative analyses of disease risk genes belonging to the acyl-CoA synthetase medium-chain (ACSM) family in human liver and cell lines. Biochem Genet., 2009, 47(9–10): 739-748

[51] van der Sluis R, Erasmus E. Xenobiotic/medium chain fatty acid: CoA ligase - a critical review on its role in fatty acid metabolism and the detoxification of benzoic acid and aspirin. Expert Opin Drug Metab Toxicol., 2016, 12(10): 1169-1179

[52] Chen X, Li X, Xu X, et al.. Ferroptosis and cardiovascular disease: role of free radical-induced lipid peroxidation. Free Radic Res., 2021, 55(4): 405-415

[53] Zheng H, Shi L, Tong C, et al.. circSnx12 Is Involved in Ferroptosis During Heart Failure by Targeting miR-224-5p. Front Cardiovasc Med., 2021, 8656093

[54] Tingberg E, Ohlin AK, Gottsater A, et al.. Lipid peroxidation is not increased in heart failure patients on modern pharmacological therapy. Int J Cardiol., 2006, 112(3): 275-281

[55] Kiyuna LA, Albuquerque RPE, Chen CH, et al.. Targeting mitochondrial dysfunction and oxidative stress in heart failure: Challenges and opportunities. Free Radic Biol Med., 2018, 129: 155-168

[56] Halliwell B. Biochemistry of oxidative stress. Biochem Soc Trans., 2007, 35(Pt 5): 1147-1150

[57] Mali VR, Palaniyandi SS. Regulation and therapeutic strategies of 4-hydroxy-2-nonenal metabolism in heart disease. Free Radic Res., 2014, 48(3): 251-263

[58] Li H, Hastings MH, Rhee J, et al.. Targeting Age-Related Pathways in Heart Failure. Circ Res., 2020, 126(4): 533-551

[59] Jhund PS, McMurray JJ. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. Heart., 2016, 102(17): 1342-1347

[60] Zhang Z, Yang Z, Wang S, et al.. Targeting MAPK-ERK/JNK pathway: A potential intervention mechanism of myocardial fibrosis in heart failure. Biomed Pharmacother., 2024, 173116413

[61] Leach JP, Heallen T, Zhang M, et al.. Hippo pathway deficiency reverses systolic heart failure after infarction. Nature., 2017, 550(7675): 260-264

[62] Zhang Y, Chen B. Silencing circ_0062389 alleviates cardiomyocyte apoptosis in heart failure rats via modulating TGF-beta1/Smad3 signaling pathway. Gene., 2021, 766145154

[63] Chen Z, Yao H, Yao X, et al.. Calotropin attenuates ischemic heart failure after myocardial infarction by modulating SIRT1/FOXD3/SERCA2a pathway. Biomed Pharmacother., 2024, 179117384

RIGHTS & PERMISSIONS

The Author(s), under exclusive licence to Huazhong University of Science and Technology